EFFECT OF TRANSDERRMAL TESTOSTERONE ON THE QUALITY OF LIFE OF MEN WITH ANDROGEN DEFICIENCY AND CHRONIC PROSTATITIS IN ROUTINE CLINICAL PRACTICE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. To evaluate the effect of Androgel® on the quality of life of patients with androgen deficiency (hypogonadism) and chronic prostatitis in everyday practice. Materials and methods. This open multicenter observational noninterventional study comprised 401 men with testosterone deficiency and chronic prostatitis who were treated with topical applications of 1% testosterone gel of (Androgel®) at a dose of 50 or 100 mg in routine clinical practice for three months. The primary endpoint was the health related quality of life. Also, the patients filled out AMS, I-PSS, NIH-CPSI questionnaires to assess the quality of life related to chronic prostatitis, lower urinary tract symptoms, and aging. Secondary endpoints included changes in the overall score of the International Index of Erectile Function (IIEF-5), changes in body weight and waist circumference, the reasons for treatment discontinuation and any adverse events that occurred during treatment. Results. Mean total testosterone levels at baseline and three months were 9.5 (95% CI 9.2-9.7) nmol/L and 16.5 (95% CI 16.1-16.9) nmol/l (p<0.001), respectively. There were statistically significant (p<0.001) differences in scores on all questionnaires. Mean scores at baseline and at three months for AMS, IIEF-5, I-PSS, NIH-CPSI questionnaires were 44.6 (95% CI 43.2-45.9) and 25.8 (95% CI 24.8-26.7); 12.7 (95% CI 12.2-13.2) and 19.3 (95% CI, 18.8-19.8); 14.5 (95% CI 13.7-15.3) and 5.6 (95% CI 5.2-6.1); 27.8 (95% CI 26,5-29.1) and 10.0 (95% CI 9.1-10.9), respectively. There were positive changes in body weight and waist circumference: at baseline and three months these parameters were 95 (95% CI 93.6-96.3) and 91.4 (95% CI 90.1-92.7) kg and 102.9 (95% CI 101.8-104.1) and 98.3 (95% CI 97.3-99.3) cm, respectively. No clinically significant adverse events were observed during follow-up. Conclusions. Transdermal therapy with 1% testosterone gel (Androgel®) is highly effective and safe in the management of androgen deficiency (hypogonadism). Its use in patients with chronic prostatitis and hypogonadism results in an improvement in low urinary tract symptoms, symptoms of chronic prostatitis, alleviates pelvic pain and thus leads to significant improvements in the quality of life.

Full Text

Restricted Access

About the authors

A. Z Vinarov

I.M. Sechenov First MSMU of Minzdrav of Russia (Sechenov University)

Email: avinarov@mail.ru
Dr.Med.Sci., Prof. at the Department of Urology

R. V Rozhivanov

ational Medical Research Center of Endocrinology of Minzdrav of Russia

Email: rrozhivanov@mail.ru
Dr.Med.Sci.

References

  1. Dedov I.I., Mel’nichenko G.A., Rozhivanov R.V., Kurbatov D.G. Guidelines on the diagnosis and treatment of testosterone deficiency (hypogonadism) in men. A draft. Problemy endokrinologii. 2015;5(61 (5):60-71.
  2. Dedov I.I., Mel’nichenko G.A., Rozhivanov R.V., Kurbatov D.G. Guidelines on the diagnosis and treatment of testosterone deficiency (hypogonadism) in men. Problemy endokrinologii. 2016;6:62(6):78- 80.
  3. Kogan M.I., Ibishev Kh.S., Chernyi A.A., Ferzauli A.Kh. Clinical characteristics of chronic bacterial prostatitis with concurrent testosterone deficiency. Meditsinskii vestnik Bashkortastana. 2013;8(2):91 -94.
  4. Kurbatov D.G., Kuznetskii Yu.Ya., Petrichko M.I. Interrelation of the syndrome of chronic pelvic pain and androgen deficiency. Andrologiya i genital’naya khirurgiya. Tezisy nauchnykh trudov Vserossiiskogo kongressa po andrologii. 2007. S. 21.
  5. Gorbachinsky I., Akpinar H., Assimos D.S. Metabolic syndrome and urological diseases. Rev Urol. 2010;12(4):157-180.
  6. URL: http://www.grls.rosminzdrav.ru
  7. Vinarov A.Z., Spivak L.A., Rokhlikov I.M., Vasilevskii R.P., Razova L.V. Effect of testosterone therapy (1% transdermal gel) on the quality of life of men with androgen deficiency under routine clinical practice: a 6-month follow-up study. Andrologiya i genital’naya khirurgiya. 2016;4(17):3-11.
  8. Zengerling F., Schrader A.J., Cronauer M.V. et al. The «Aging Males’ Symptoms» Scale (AMS): predictive value for lowered circulating androgens. Aging Male. 2012;15(4):253-257. doi: 10.3109/13685538.2012.729232.
  9. Saad F., Aversa A., Isidori A.M. et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. European Journal of Endocrinology. 2011 ; 165(5):675-685. doi: 10.1530/eje-11-0221.
  10. Saad F., Gooren L., Haider A., Yassin A. An Exploratory Study of the Effects of 12 Month Administration of the Novel Long-Acting Testosterone Undecanoate on Measures of Sexual Function and the Metabolic Syndrome. Syst Biol Reprod Med. 2007;53(6):353-357. doi: 10.1080/01485010701730880.
  11. Haider A., Gooren LJ.G., Padungtod P., Saad F. Improvement of the Metabolic Syndrome and of Non-alcoholic Liver Steatosis upon Treatment of Hypogonadal Elderly Men with Parenteral Testosterone Undecanoate. Exp Clin Endocrinol Diabetes. 2009;118(03):167-171. doi: 10.1055/s-0029-1202774.
  12. Moon du G., Park M.G., Lee S.W. et al. The efficacy and safety of testosterone undecanoate (Nebido((R))) in testosterone deficiency syndrome in Korean: a multicenter prospective study. J Sex Med. 2010;7(6):2253-2260. doi: 10.1111/j.1743-6109.2010.01765.x.
  13. Giltay E.J., Tishova Y.A., Mskhalaya G.J. et al. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med. 2010;7(7):2572-2582. doi: 10.1111/j.1743-6109.2010.01859.x.
  14. Zitzmann M., Mattern A., Hanisch J. et al. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med. 2013;10(2):579-588. doi: 10.1111/j.1743-6109.2012.02853.x.
  15. Kogan M.I., Savzikhanov R.T. The effect of androgen replacement therapy on the symptoms of the lower urinary tract. Materialy Mezhdunarodnogo kongressa po Andrologii: pril. k zhur. Andrologiya i genital’naya khirurgiya. 2009;2:133-134.
  16. Tyuzikov I.A., Kalinchenko S.Yu., Vorslov L.O., Grekov E.A. Correction of androgen deficiency in chronic prostatitis as a pathogenetic method of overcoming the ineffectiveness of standard antibiotic therapy in the setting of growing antibiotic resistance. Effektivnaya farmakoterapiya v urologii. 2013;2:55-63.
  17. Basaria S., Lakshman K.M. Safety and efficacy of testosterone gel in the treatment of male hypogonadism. Clin Interv Aging. 2009;4:397-412. doi: 10.2147/cia.s4466.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies